I think this really needs to be investigated pront
Post# of 148050
A switch from subcutaneous to intravenous could make a huge difference with a huge effect on p values.
IV introduction of LL could be like kicking in the afterburners. All data on IV experience in any trials needs to be shown to the FDA along with CD12 results.
We must get the go ahead for IV!
Read More: https://investorshangout.com/messages/view?id...z6kUY4Az00